Ian D. Pavord

TL;DR: In this article , the typical symptoms and abnormal physiology of variable airflow limitation permits the recognition of asthma, and the identification of further features, such as eosinophilic or type 2 inflammation, allows a compound diagnostic label of eOSINophilic asthma, conveys key information about future exacerbation risk and likely treatment responsiveness.

TL;DR: Treatment with mepolizumab in this population with significant impairment and high risk for side effects from OCS provides an important therapeutic alternative and resulted in significant improvements in asthma control and quality of life, despite a reduced OCS dose.

TL;DR: The observation that in asthma the airway smooth muscle (ASM) was infiltrated by mast cells, suggesting that the airways obstruction and AHR was due to an ASM mast cell myositis, emphasizes the importance of microlocalization as an organizing principle in physiological responses to airway inflammation.

TL;DR: There are important aspects of the study design that cast doubt on the claim of Cowan et al that ‘modified responses’ to corticosteroids occur in patients with non-eosinophilic asthma.